OBJECTIVES: To assess the safety of benznidazole use in adult patients with chronic Chagas' disease. METHODS: The Naranjo algorithm was applied to classify the causality of adverse drug reactions (ADRs). RESULTS: In total, 190 patients were treated with benznidazole over a period of 4-180 days (mean 58.90 ± 36.54 days) with a dose of 50-500 mg/day (221.33 ± 57.16 mg/day). Of the 190 patients treated, 93 had ADRs and 59 of these interrupted treatment. There was a higher incidence of ADRs among female and young adult patients. There was a higher incidence of ADRs during the first 30 days of treatment. Interruption of treatment was more frequent in women. Among the patients who interrupted treatment, 39 had mild ADRs, 19 had moderate ADRs and 1 had a severe ADR. There were no interruptions in treatment for 97 patients without ADRs. The survival curves indicated that the time until interruption of treatment in patients with moderate and severe ADRs was lower than in patients with mild or no ADRs. The most frequent disorders were in the skin (26.3%), gastrointestinal system (9.5%) and nervous system (5.3%). CONCLUSIONS: The Naranjo algorithm was a useful tool to reduce the underreporting of ADRs. Events were common, but were associated with low morbidity and were reversible upon discontinuation of drug treatment. Moreover, there were no fatal events; therefore, benznidazole treatment was considered safe.
OBJECTIVES: To assess the safety of benznidazole use in adult patients with chronic Chagas' disease. METHODS: The Naranjo algorithm was applied to classify the causality of adverse drug reactions (ADRs). RESULTS: In total, 190 patients were treated with benznidazole over a period of 4-180 days (mean 58.90 ± 36.54 days) with a dose of 50-500 mg/day (221.33 ± 57.16 mg/day). Of the 190 patients treated, 93 had ADRs and 59 of these interrupted treatment. There was a higher incidence of ADRs among female and young adult patients. There was a higher incidence of ADRs during the first 30 days of treatment. Interruption of treatment was more frequent in women. Among the patients who interrupted treatment, 39 had mild ADRs, 19 had moderate ADRs and 1 had a severe ADR. There were no interruptions in treatment for 97 patients without ADRs. The survival curves indicated that the time until interruption of treatment in patients with moderate and severe ADRs was lower than in patients with mild or no ADRs. The most frequent disorders were in the skin (26.3%), gastrointestinal system (9.5%) and nervous system (5.3%). CONCLUSIONS: The Naranjo algorithm was a useful tool to reduce the underreporting of ADRs. Events were common, but were associated with low morbidity and were reversible upon discontinuation of drug treatment. Moreover, there were no fatal events; therefore, benznidazole treatment was considered safe.
Authors: Irene Losada Galván; Olaya Madrid Pascual; Juan María Herrero-Martínez; Ana Pérez-Ayala; Manuel Lizasoain Hernández Journal: Am J Trop Med Hyg Date: 2019-06 Impact factor: 2.345
Authors: Neide M Moreira; Franciele d N Santos; Max Jean d O Toledo; Solange M F d Moraes; Eduardo J d A Araujo; Debora d M G Sant'Ana; Silvana M d Araujo Journal: Int J Exp Pathol Date: 2013-11-01 Impact factor: 1.925
Authors: Gilberto Marcelo Sperandio da Silva; Mauro Felippe Felix Mediano; Pedro Emmanuel Alvarenga Americano do Brasil; Mayara da Costa Chambela; Joyce Almeida da Silva; Andrea Silvestre de Sousa; Sergio Salles Xavier; Andrea Rodrigues da Costa; Roberto Magalhães Saraiva; Alejandro Marcel Hasslocher-Moreno Journal: Antimicrob Agents Chemother Date: 2014-08-11 Impact factor: 5.191
Authors: Cauê B Scarim; Cleverton R de Andrade; João A da Rosa; Jean L Dos Santos; Chung M Chin Journal: Int J Exp Pathol Date: 2018-10-15 Impact factor: 1.925
Authors: I Molina; F Salvador; A Sánchez-Montalvá; B Treviño; N Serre; A Sao Avilés; B Almirante Journal: Antimicrob Agents Chemother Date: 2015-07-20 Impact factor: 5.191
Authors: Derek L Fong; Annie E Torrence; Keith W Vogel; Diane E Stockinger; Veronica Nelson; Robert D Murnane; Audrey Baldessari; LaRene Kuller; Michael Agy; Hans-Peter Kiem; Charlotte E Hotchkiss Journal: Comp Med Date: 2014-02 Impact factor: 0.982
Authors: Cristina Vázquez; Elisa García-Vázquez; Bartolomé Carrilero; Marina Simón; Fuensanta Franco; Maria A Iborra; Luis J Gil-Gallardo; Manuel Segovia Journal: Am J Trop Med Hyg Date: 2020-05 Impact factor: 2.345